BT1718

E1266365 UNEXPLORED

BT1718 is an experimental cancer drug candidate developed by Bicycle Therapeutics that uses a bicyclic peptide-based approach to selectively target and kill tumor cells.

All labels observed (1)

Label Occurrences
BT1718 canonical 1

How this entity was disambiguated

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.